Novo Nordisk Other Non-Current Liabilities 2012-2026 | NVO

Novo Nordisk other non-current liabilities for the quarter ending March 31, 2026 were $0.939B, a 23.13% decline year-over-year.

  • Novo Nordisk other non-current liabilities for 2025 were $1.027B, a 19.34% decline from 2024.
  • Novo Nordisk other non-current liabilities for 2024 were $1.273B, a 28.19% increase from 2023.
  • Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.

Novo Nordisk Other Non-Current Liabilities 2012-2026 | NVO

  • Novo Nordisk other non-current liabilities for 2025 were $1.027B, a 19.34% decline from 2024.
  • Novo Nordisk other non-current liabilities for 2024 were $1.273B, a 28.19% increase from 2023.
  • Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B